NASDAQ · SCPH
scPharmaceuticals Inc.
$5.67$0.00 (0.0%)
scPharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.71% below the high.
Loading market information…
NASDAQ · INZY · USD
Stock price, earnings
Quote as of Jul 1, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Inozyme Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 7, 2023 |
| -$0.29+9.38% vs estimate |
| $0.00 |
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.67$0.00 (0.0%)
scPharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.71% below the high.
$5.00$0.00 (0.0%)
2seventy bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.66% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$8.54-$0.64 (-6.97%)
Catabasis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.27% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
